NASDAQ · Drug Manufacturers - Specialty & Generic

BGM Group Ltd. (BGM) Stock

$0.30 -1.10% NASDAQ: BGM Healthcare

Operating from Chengdu, People's Republic of China, BGM Group Ltd. engages in the manufacturing and supply of active pharmaceutical ingredients (APIs), traditional Chinese medicine (TCM) derivatives, and various other related products across China.

Valuation

MetricValue
Price$0.30
Market Cap$59.61M
P/E Ratio-1.82
P/B Ratio0.10
P/S Ratio1.57
EPS (TTM)$-0.20
52-Week High$11.80
52-Week Low$0.25
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-6.96%
ROA-4.60%
ROCE-3.21%
Gross Margin12.79%
Operating Margin-33.18%
Net Margin-52.59%
Debt/Equity0.01
Current Ratio1.24

Annual Financials (USD)

Metric20212022202320242025
Revenue$57.0M$65.0M$46.0M$25.0M$38.0M
Operating Profit$2.0M$2.0M$-3.0M$-1.0M$-13.0M
Net Profit$3.0M$1.0M$-8.0M$-1.0M$-20.0M
EPS$0.45$0.15$-1.08$-0.20$-0.18
Op Margin4.2%3.2%-5.6%-2.3%-33.2%

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$75.0M$65.0M$51.0M$53.0M$434.0M
Total Liabilities$19.0M$10.0M$7.0M$9.0M$42.0M
Cash$10.0M$14.0M$7.0M$10.0M$10.0M
Borrowings$8.0M$2.0M$1.0M$0$2.0M

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$0$13.0M$0$1.0M$-2.0M
Investing Cash Flow$-28.0M$-7.0M$-8.0M$-3.0M$-2.0M
Financing Cash Flow$0$0$0$0$0
Net Cash Flow$1.0M$2.0M$-8.0M$2.0M$0
Free Cash Flow$-3.0M$9.0M$-3.0M$-3.0M$-4.0M

Valuation & Return Ratios

MetricValue
PEG Ratio0.00
EV / EBITDA-9.25
FCF Yield-4.01%
Quick Ratio0.67
Interest Coverage0.00
Return 1Y-96.18%
Return 3Y-92.63%
Return 5Y-98.60%

Ownership

Insiders Held23.83%
Institutions Held0.06%
Institutions Float Held0.07%
Institutional HolderSharesReport Date
HRT Financial LP48,1742026-03-31
Geode Capital Management, LLC46,9612026-03-31
State Street Corporation46,5322026-03-31
Susquehanna International Group, LLP15,7372026-03-31
Two Sigma Securities, LLC16,0752026-03-31

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
ANIP $82.63 +3.44% 24.92 $1.88B 0.00%
AVDLAvadel Pharmaceuticals plc $21.64 +0.00% 431.08 $2.12B 0.00%
CLOV $4.76 +2.15% 48.35 $2.47B 0.00%
EWTX $43.52 -2.03% -14.63 $4.68B 0.00%
GPCRStructure Therapeutics Inc. $53.36 -3.23% -20.21 $3.07B 0.00%

About BGM Group Ltd.

Operating from Chengdu, People's Republic of China, BGM Group Ltd. engages in the manufacturing and supply of active pharmaceutical ingredients (APIs), traditional Chinese medicine (TCM) derivatives, and various other related products across China. The company's pharmaceutical portfolio includes an array of licorice-based items: Gan Di Xin, an oral medication for cough and expectorant relief; Qilian Shan Licorice Extract, serving as a raw material for pharmaceutical firms to produce conventional licorice tablets; and Qilian Shan licorice liquid extract, a key ingredient utilized by medical preparers for crafting compound licorice oral solutions. BGM also provides Qilian Shan oxytetracycline tablets, formulated to prevent and treat a range of ailments in poultry (chickens, turkeys), livestock (cattle, swine), and humans, in addition to Qilian Shan oxytetracycline APIs for use by pharmaceutical manufacturers. Beyond APIs, the company produces TCM derivatives such as Ahan antibacterial paste, which is designed for managing stubborn chronic skin conditions. Its diverse offerings also encompass heparin products, including heparin sodium preparations essential for pharmaceutical companies developing treatments for cardiovascular and cerebrovascular diseases, as well as hemodialysis applications. Furthermore, BGM supplies natural food products like Zhu Xiaochang sausage casings for culinary use. In the agricultural sector, it offers Xiongguan organic fertilizers, which enhance crop yields, improve soil chemical characteristics, and alleviate compaction, alongside Xiongguan organic-inorganic compound fertilizers engineered to promote superior plant development. Established in 2019, the company operated as Qilian International Holding Group Limited until adopting its current name, BGM Group Ltd, in October 2024.

BGM Group Ltd. is led by CEO Chen Xin, employs 298 people, headquartered in CN, publicly traded since 2003.

BGM Group Ltd. (BGM) stock trades at $0.30 with a market capitalization of $59.61M. The stock is valued at a price-to-earnings (P/E) ratio of -1.82, price-to-book of 0.10, price-to-sales of 1.57. Over the past 52 weeks the stock has ranged between $0.25 and $11.80, and currently trades 97.5% below its 52-week high.

On profitability, BGM Group Ltd. generates a return on equity (ROE) of -6.96%, return on capital employed of -3.21%, an operating margin of -33.18%, a net profit margin of -52.59%.

Official website: www.bgmgroupltd.com

Related Healthcare Stocks

LLY Drug Manufacturers - General $1185.71 -0.52% JNJ Drug Manufacturers - General $259.24 +0.88% ABBV Drug Manufacturers - General $246.04 +0.89% UNH Medical - Healthcare Plans $407.08 +0.77% MRK Drug Manufacturers - General $128.57 +0.16% NVS Drug Manufacturers - General $158.83 -0.64% NVO Biotechnology $51.58 +1.22% TMO Medical - Diagnostics & Research $594.00 +2.41% AMGN Drug Manufacturers - General $387.64 -1.39% ABT Medical - Devices $108.03 +0.70% GILD Drug Manufacturers - General $132.73 -1.18% PFE Drug Manufacturers - General $26.74 +2.06%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides